Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) has delivered promising news with the announcement of positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial. The trial successfully met its primary endpoint by demonstrating improved physiologic liver function in subjects with stage 3 or greater fibrosis based on the AGILE 3+ criteria. Furthermore, the treatment was well tolerated over the course of four months, and all additional secondary endpoints were also met.

As a result of this announcement, the pre-market trading of $HEPA is experiencing a substantial surge. Currently valued at $15.14, the stock has soared by $6.23 (+69.92%).

In other developments, Loop Capital has downgraded Apple Inc. (Nasdaq: AAPL) from Buy to Hold. 

In pre-market, $AAPL is trading at $173.42, showing a decline of $1.74 (-0.99%).

Additionally, Plug Power Inc. (Nasdaq: PLUG) has secured three significant projects for five megawatt (MW) electrolyzers. The projects with Ardagh Glass Limmared AB, Hydro Havrand, and the APEX Group mark the first-ever utilization of industrial-scale green hydrogen in processes related to glass manufacturing, aluminum recycling, and steel manufacturing.

$PLUG is currently trading at $8.07 in pre-market, experiencing a positive gain of $0.34 (+4.40%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)